Wells Fargo maintains Tandem Diabetes Care at Overweight, lowers price target to $25 from $27
Wells Fargo kept Tandem Diabetes Care's rating at Overweight but reduced its price target to $25 from $27, a 7.4% cut. This implies a 39.0% upside from the Nov 5 close of $17.99.
How this was made

The 30-second read
Why it matters
Analyst target revisions often lead to short-term price moves, especially for small-cap biotech stocks.
Market read
A fresh downgrade can trigger sell pressure, offering a potential short opportunity for traders.
What to watch
Recent product launches or pipeline progress not reflected in the target.
Background
Wells Fargo's research team adjusted its outlook for Tandem Diabetes Care, reflecting new expectations for growth and profitability.
Ticker impact
Wells Fargo lowered its price target for Tandem Diabetes Care to $25 from $27, indicating a fresh analyst downgrade.
likely downward pressure as investors price in the lower target
Analyst price target cuts are immediate signals that can trigger short-term sell-offs.
Market effects
May slightly dampen sentiment in the diabetes device sector.
Limited to U.S. biotech/medical device investors.
Minimal global impact.
Counterpoint
The target cut could be an overreaction; the stock may be undervalued relative to peers.
Key entities
- companyTandem Diabetes Care
Medical device maker focused on insulin pumps.
- analyst_firmWells Fargo
Provides equity research and price targets.
